Description
Low-dose colchicine reduces the risk of cardiovascular events after myocardial infarction (MI). The purpose of this study was to assess the effect of colchicine post-MI on coronary plaque morphology in non-culprit segments by optical coherence tomography (OCT). Participants were randomly assigned to treatment (Colchicine 0.5mg once a day orally for 12 month) or control group (placebo tablet to take once a day for 12 months).
| Date made available | 2025 |
|---|---|
| Publisher | South Australian Health and Medical Research Institute |
| Temporal coverage | 2018 - 2022 |
| Date of data production | 2018 - 2022 |
| Geographical coverage | South Australia, Victoria, Queensland, New South Wales and Western Australia |
Research output
- 1 Article
-
Assessing the impact of colchicine on coronary plaque phenotype after myocardial infarction with optical coherence tomography: rationale and design of the COCOMO-ACS study
Montarello, N. J., Singh, K., Sinhal, A., Wong, D. T. L., Alcock, R., Rajendran, S., Dautov, R., Barlis, P., Patel, S., Nidorf, S. M., Thompson, P. L., Salagaras, T., Butters, J., Nerlekar, N., Di Giovanni, G., Ottaway, J. L., Nicholls, S. J. & Psaltis, P. J., 25 Aug 2021, In: Cardiovascular Drugs and Therapy.Research output: Contribution to journal › Article › peer-review
22 Link opens in a new tab Citations (Scopus)
Cite this
- DataSetCite